Recent Updates
Recently added Catalysts
AGMB Positive Sentiment

Agomab to Participate in Upcoming Conferences

Thursday, May 14, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Agomab Therapeutics NV has announced its participation in several upcoming industry and investor conferences. Key presentations will include a poster on AGMB-447, which targets idiopathic pulmonary fibrosis, and fireside chats at major investor events. These engagements aim to showcase Agomab's advancements in fibro-inflammation treatments.
Price reaction · baseline $11.18 (2026-05-13 close) · hit pre-market · clean, no other AGMB news in the window
day 0 close · peak
-1.3%

Market Sentiment Analysis

POSITIVE FACTORS

  • Participation in multiple high-profile conferences.
  • Presentation of promising research on AGMB-447.
  • Engagement with investors and industry leaders.

Full Press Release Details

Antwerp, Belgium, May 14, 2026 – Agomab Therapeutics NV (Nasdaq: AGMB) (“Agomab”), a clinical-stage biopharmaceutical company focused on fibro-inflammation, today announced that members of the management team will participate in the following upcoming industry and investor conferences:
• ATS International Conference 2026. Poster Board #904 titled ‘AGMB-447, an Inhaled Lung-Restricted TGFβR1/ALK5 Inhibitor Intended for the Treatment of Idiopathic Pulmonary Fibrosis, Shows Robust Anti-Fibrotic Activity and Target Engagement in Preclinical Species and Healthy Subjects’ on Wednesday, May 20, 2026 at 8:15 AM ET in Orlando, Florida.
• H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ. Fireside chat on Tuesday, May 19, 2026 at 1:30 PM ET in New York, NY.
• 2026 RBC Capital Markets Global Healthcare Conference. Fireside chat on Wednesday, May 20, 2026 at 8:00 AM ET in New York, NY.
• JPM European Healthcare Symposium. Wednesday, June 10, 2026 in London, UK.
• BIO International Convention. Monday, June 22 – Thursday, June 25, 2026 in San Diego, California.
• 2026 Leerink Partners Therapeutics Forum. One-on-one investor meetings on Wednesday, July 15, 2026 in Boston, MA.

Frequently Asked Questions

What conferences will Agomab participate in?

Agomab will participate in several conferences, including ATS International Conference and BIO International Convention.

What is AGMB-447?

AGMB-447 is an inhaled TGFβR1/ALK5 inhibitor aimed at treating idiopathic pulmonary fibrosis.

When is the ATS International Conference?

The ATS International Conference will be held on May 20, 2026, in Orlando, Florida.

Where will the BIO International Convention take place?

The BIO International Convention will take place in San Diego, California, from June 22 to June 25, 2026.

ShareAdd on Google
Tags: AGMB Viatris Investor Conferences Healthcare Agomab Therapeutics AGMB-447 pulmonary fibrosis ATS International Conference biohealth conferences
Last updated: May 14, 2026

Biotech snapshot

Lead asset
AGMB-129Phase 2
Fibrostenotic Crohn's Disease →